about
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissuesATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cellsHIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant VariantsPotent synergism of the combination of fluconazole and cyclosporine in Candida albicansFibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouseDifferent modalities of intercellular membrane exchanges mediate cell-to-cell p-glycoprotein transfers in MCF-7 breast cancer cells.Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance.A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell linesA retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cellsFluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells.Interaction of common azole antifungals with P glycoproteinEssential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.A comprehensive continuous-time model for the appearance of CGH signal due to chromosomal missegregations during mitosis.Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.Bioactive taxoids from the Japanese yew Taxus cuspidata.Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924Imaging recognition of multidrug resistance in human breast tumors using 99mTc-labeled monocationic agents and a high-resolution stationary SPECT system.New therapies for ovarian cancer.PRDM1 is a tumor suppressor gene in natural killer cell malignancies.Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group.MDR1 gene expression in primary colorectal carcinomas.Characterisation of a new mouse monoclonal antibody (ONS-M21) reactive with both medulloblastomas and gliomas.Expression of anionic glutathione S transferase (GST pi) gene in carcinomas of the uterine cervix and in normal cervices.Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers.Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell lineMetabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linkerReversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme.Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoproteinExpression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas.P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseasesComparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomasThe molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research.Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patientsFour cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative GroupIn vitro and in vivo potentiation of chloroquine against malaria parasites by an enantiomer of amlodipine.Use of a cloned multidrug resistance gene for coamplification and overproduction of major excreted protein, a transformation-regulated secreted acid protease.
P2860
Q24633406-B203E659-E0D1-45AB-A805-88E7FEB5DAA6Q24650215-5A2F20DC-DE9B-4912-96B2-F40F9EAB6AFCQ27650325-02300747-84FB-4735-BFF3-CC323FC2428CQ28344597-EF7896EE-3858-4DAC-8BBD-DCA4ED941579Q28509638-BE7070DA-474F-4410-B9D3-E7BA52315210Q30506221-A5ECA312-FCA6-43C4-8B98-0F91C55D1554Q32063216-3788D9C8-95FF-4DE4-B2E0-12C7C9DC4950Q33377470-64C51EB9-FA39-4447-AE52-442BC740D8EBQ33576745-C2053E1C-5E83-4013-B741-DA631872251BQ33582717-9A06CB05-E986-43C1-95DA-3A35CFFA61C3Q33593689-78437EDE-706D-4A84-906A-27AD7D520F87Q33826871-83FBE7A8-0B48-4E43-A983-CDF934F59E1BQ34104641-88F130E7-3E72-4D2E-9A6D-24D87F840059Q34287731-9A7A263E-23B3-4FAA-8512-EFC75A8BD3D1Q34325538-11E64E51-89F8-453B-AD70-E4CECAE8428EQ34450507-2BA3545B-6671-4C31-A8E0-C75D241A56D1Q34587524-0CB138A6-65C5-4502-8B56-DFF74E558652Q34674256-B2AB5A64-0C21-43D4-B4F6-09BB03ECE03BQ34711648-1E713020-3C4D-476C-A47C-3E0B04121E52Q35259954-4122456F-655E-40B5-B584-B7D2F4D98134Q35647475-A25C142F-98C5-46C0-A072-EB6AC699CF8DQ35976246-98FC7097-5629-4B42-9F62-723ED7E1FB7CQ35977382-7FAF96A0-A2CC-47BB-900B-9CF029E11742Q35977393-3A207E8C-C25E-4DC2-8C5F-A44A2D5C171DQ35977752-51352DFC-06B6-4570-AAD5-5E48E18A6AB4Q35982922-3043B9CF-ACD1-4416-A886-18C8034D52FDQ35983196-5FD0EA38-A128-4035-8CF5-45F59C5F7F78Q35984767-A491FFE4-74B8-4AD3-AE21-49328B04CB10Q36079473-D34C78CA-5FBD-4CEA-8DE1-A73897F11DD7Q36079966-E726F363-D8DF-4476-924F-D7279777F98EQ36080042-3347AD36-C23F-42FE-BC7A-73AEF6188535Q36115251-17CAEE22-CDB8-4870-92C9-58AB1F6B8DC4Q36115974-69256E68-B263-4B69-A373-DEC71E825441Q36201459-AF4544A3-29F4-4AEE-AB6B-71B3952486ADQ36291762-A0572D10-20B3-447D-95DF-5DE633864F64Q36365560-A22006A3-E4B9-45EF-B04B-671987E7B51BQ36620717-344EB9E2-720B-46EA-9AE6-E34C78E7B033Q36678707-700EF2B0-0183-4549-9C49-9FEE8F861C8DQ36754071-F9CC3489-06B4-40AD-8181-93FBD62CC509Q36793191-DFF67ECF-D328-40A6-814E-1C93DF59BC98
P2860
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Multiple-drug resistance in human cancer.
@en
Multiple-drug resistance in human cancer.
@nl
type
label
Multiple-drug resistance in human cancer.
@en
Multiple-drug resistance in human cancer.
@nl
prefLabel
Multiple-drug resistance in human cancer.
@en
Multiple-drug resistance in human cancer.
@nl
P1476
Multiple-drug resistance in human cancer.
@en
P2093
P304
P356
10.1056/NEJM198705283162207
P407
P577
1987-05-01T00:00:00Z